Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock plunged on Thursday after the company cut its annual guidance. Benzinga · Aug 7, 2025
Is Insulet Stock Outperforming the Dow? Insulet has outperformed the Dow recently, and analysts remain strongly optimistic about the stock’s prospects. Barchart · Dec 27, 2024
6 Analysts Have This to Say About Tandem Diabetes Care Within the last quarter, Tandem Diabetes Care (NASDAQ:TNDM) has observed the following analyst ratings: Benzinga · May 5, 2022
Tandem Diabetes' Q1 Bottom-Line Slide Deeper Into Red Despite Sales Growth Tandem Diabetes Care Inc (NASDAQ:TNDM) posted Q1 losses of $(0.23) deeper than $(0.08) posted a year ago and missing the consensus of $(0.07). Sales increased 25% to $175.91 million, beating the consensus of $168.43 million. Worldwide pump shipments increased 11% Y/Y to 28,095. The gross margin remained almost unchanged at 52%. The company… Benzinga · May 5, 2022
Recap: Tandem Diabetes Care Q1 Earnings Tandem Diabetes Care (NASDAQ:TNDM) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Benzinga · May 4, 2022
Tandem Diabetes Reports Mixed Q4 Earnings, Issues Better Than Expected FY22 Outlook Tandem Diabetes Care Inc (NASDAQ: TNDM) reported Benzinga · Feb 23, 2022
Expert Ratings For Tandem Diabetes Care Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ:TNDM) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Benzinga · Feb 23, 2022